Eyetech Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Eyetech Pharmaceuticals believes that blocking angiogenesis is the best route to improved therapy for age-related macular degeneration and diabetic macular edema, degenerative conditions that frequently and quickly lead to serious vision loss and blindness. The company in-licensed a compound from Gilead Sciences, about to enter pivotal clinical trials, that it thinks does just that.
You may also be interested in...
Tioga Pharmaceuticals Inc.
Tioga Pharmaceuticals has been formed to develop asimadoline, to treat pain in patients with irritable bowel syndrome and other gastrointestinal diseases. But unlike in-licensers that seek many shots on goal to balance risk, it is singularly focused on development of this asset.
Tioga Pharmaceuticals Inc.
Tioga Pharmaceuticals has been formed to develop asimadoline, to treat pain in patients with irritable bowel syndrome and other gastrointestinal diseases. But unlike in-licensers that seek many shots on goal to balance risk, it is singularly focused on development of this asset.
The Key to Turning Technology into Products? Management.
The fundamental business model for platform technology companies hasn't changed: Build the platform, and apply the resulting discovery capability to internal product development while leveraging its value to raise cash or barter for resources. But investors today prefer companies that can articulate a short route to proof-of-concept data,. And unlike 6-10 years ago, more start-ups are now being formed around clinically savvy drug development teams that are better able to select alternative paths to near-term opportunities--be it in-licensing or even M&A--that allows companies greater flexibility.